M. Garrett

CPI203, a BET inhibitor, down-regulates a consistent set of DNA synthesis genes across a wide array of glioblastoma lines.

This study identifies CPI203, a BET inhibitor, as a compound that consistently down-regulates DNA synthesis genes across multiple glioblastoma lines.

Resistance patterns in drug-adapted cancer cell lines reflect complex evolution in clinical tumors

This study identifies drug-resistant sublines of TNBC cell lines and finds that resistance mechanisms are unique and unpredictable, suggesting new potential drug targets.

De novo lipogenesis pathway is a vulnerability in IDH1 mutant glioma

This study identifies de novo lipogenesis as a vulnerability in IDH1 mutant gliomas, showing that HDAC inhibition and FASN targeting reduce tumor growth and improve survival.

Towards personalized auditory models: predicting individual sensorineural-hearing-loss profiles from recorded human auditory physiology

This study develops a method to predict individual sensorineural hearing loss profiles using auditory evoked potentials to personalize auditory models for hearing aids.

Epitope profiling reveals binding signatures of SARS-CoV-2 immune response and cross-reactivity with endemic HCoVs

This study maps SARS-CoV-2 antibody epitopes and identifies cross-reactive sequences with endemic HCoVs in COVID-19 patients.

The Derived-Band Envelope Following Response and its Sensitivity to Sensorineural Hearing Deficits

This study introduces a derived-band EFR (DBEFR) technique to improve frequency specificity and investigates its sensitivity to sensorineural hearing deficits in humans.

Diversity and function of maternal HIV-1-specific antibodies at the time of vertical transmission

This study isolates and characterizes HIV-specific neutralizing antibodies from a mother of a vertically infected infant, revealing their diversity and functional properties.

Injectable diblock copolypeptide hydrogel provides platform to maintain high local concentrations of taxol and local tumor control

This paper develops an injectable hydrogel to deliver paclitaxel for glioblastoma treatment, achieving high local concentrations and improved survival in mice, but tumor cells can still escape the treatment area.

Injectable diblock copolypeptide hydrogel provides platform to maintain high local concentrations of taxol and local tumor control.

This paper develops an injectable hydrogel to deliver paclitaxel for glioblastoma treatment, achieving high local concentrations and improved survival in mice, but tumor cells can still escape the treatment area.